Our current study revealed significant anti-tumor activity after HSP90 inhibition with the drug 17-AAG in the malignant, MYCN-amplified IMR-32 cells and more potent anti-tumor activity in the non-MYCN amplified SK-N-SH cells. The gene discussed is HSP90AA1; the disease is neoplasm.